about
Purinergic Receptors: Key Mediators of HIV-1 Infection and InflammationA high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entryThe Mrp Na+/H+ antiporter increases the activity of the malate:quinone oxidoreductase of an Escherichia coli respiratory mutant.The activity profile of the NhaD-type Na+(Li+)/H+ antiporter from the soda Lake Haloalkaliphile Alkalimonas amylolytica is adaptive for the extreme environment.Single site mutations in the hetero-oligomeric Mrp antiporter from alkaliphilic Bacillus pseudofirmus OF4 that affect Na+/H+ antiport activity, sodium exclusion, individual Mrp protein levels, or Mrp complex formation.P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.Catalytic properties of Staphylococcus aureus and Bacillus members of the secondary cation/proton antiporter-3 (Mrp) family are revealed by an optimized assay in an Escherichia coli host.IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.Single gene deletions of mrpA to mrpG and mrpE point mutations affect activity of the Mrp Na+/H+ antiporter of alkaliphilic Bacillus and formation of hetero-oligomeric Mrp complexesA clinical refresher course for medical scientist trainees.P2X antagonists inhibit HIV-1 productive infection and inflammatory cytokines IL-10 and IL-1β in a human tonsil explant modelPurinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 FusionP2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent FusionThe Science and Value of Diversity: Closing the Gaps in Our Understanding of Inclusion and DiversityAn inflammatory cytokine signature helps predict COVID-19 severity and death
P50
Q26774666-E3F29F95-14C4-4FBC-B612-2FA9FEE11672Q30810565-CBAE0BCA-9C9A-4BEE-8096-0440405074C1Q33554266-5E90D9DB-67CF-4FE3-9F7A-D8A7E46DF399Q34124308-3E53AB83-B907-4F08-861B-28FB330540DBQ34155423-B6B9E1A4-07E6-43B6-B612-8EC03A6DD3FBQ34261784-9665BD82-013F-4471-BC6A-6B0CDDA4F9E1Q35759663-6F30477C-C430-4C48-A2E6-5A19C6C2C728Q36150469-9AB9ABA4-9ACB-472B-9E21-8845384B5B3BQ36747253-610EF75C-CC7B-40C0-9F08-A2C8719854EDQ38188022-9CE9477B-2982-4700-9A4E-687275BCE164Q57285031-A6FE14DD-B12B-4405-9251-19E4030FA6D7Q90191907-3A881EF1-8BB3-491D-B9A0-79FF72F4A0CAQ92093856-B8FA78FC-A65B-440D-83C2-EAB157CE8DC9Q92727492-C6D95057-1D19-4BFA-8764-2637DDF0B559Q96223915-B6F42998-D4EC-4968-9156-52696266B7A1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Talia H Swartz
@ast
Talia H Swartz
@en
Talia H Swartz
@es
Talia H Swartz
@nl
type
label
Talia H Swartz
@ast
Talia H Swartz
@en
Talia H Swartz
@es
Talia H Swartz
@nl
prefLabel
Talia H Swartz
@ast
Talia H Swartz
@en
Talia H Swartz
@es
Talia H Swartz
@nl
P106
P1153
9237077800
P31
P496
0000-0003-1572-045X